Repetitive task practice (RTP) programme for Participant 005 Table 2 Baseline and Visit 18 scores for outcome assessments 
Abstract

Goal
Invasive vagus nerve stimulation (VNS) has the potential to enhance the effects of physiotherapy for upper limb motor recovery post stroke. Noninvasive, trans-auricular branch VNS (taVNS) may have similar benefits but this has not been evaluated in stroke recovery.
We sought to determine the feasibility of transcutaneous auricular VNS (taVNS) delivered alongside upper limb repetitive task-specific practice post stroke and its effects on a range of outcome measures evaluating limb function.
Materials and Methods
Thirteen participants >3 months post ischemic stroke with residual upper limb dysfunction were recruited from the community of Sheffield, UK (October -December 2016).
Participants underwent 18 x 1-hour sessions over 6 weeks in which they made repetitions of 8-10 arm movements concurrently with taVNS (NEMOS®, Cerbomed, 25 Hz, 0.1 ms pulse width) at maximum tolerated intensity (mA). An electrocardiogram and rehabilitation outcome scores were obtained at each visit. Qualitative interviews determined the acceptability of taVNS to participants.
Introduction
Approximately half of stroke survivors have persisting arm weakness, which significantly impedes activities of daily living. Upper limb interventions to enhance neuroplasticity post stroke usually involve "repetitive task-specific practice" (RTP) in which the patient makes repeated movements of the arm directed towards a functional goal.
Mounting evidence from animal and human studies suggest that stimulation of the vagus nerve (VNS) enhances the effects of RTP by boosting neuroplasticity. In rats with ischaemic stroke, delivery of VNS concurrently with "pulls" of a lever to obtain food led to more rapid recovery of the stroke-affected forelimb. 12 These improvements were associated with an enlargement of the associated motor cortex. 3 Delivery of VNS concurrently with a stimulus can also treat tinnitus (a condition caused by maladaptive plasticity), where the pairing of VNS with different auditory tones can reduce the person's perception of the unwanted sound 4 .
Several mechanisms may explain the beneficial effects of VNS on plasticity. 5 For example, VNS increases levels of brain-derived neurotrophic factor (BDNF), and IL-B (both key regulators of neuroplasticity). 56 VNS also stimulates the release of acetylcholine (ACh) and noradrenaline. 7 One study in mice post stroke found that selective obliteration of the cholinergic cortical projections from the Nucleus Basilis completely offset the effects of VNS on limb movement 8 suggesting a key role for ACh in mediating plasticity from VNS.
VNS is already a licensed treatment in humans for epilepsy and depression. In these cases, stimulators are implanted directly onto the vagus nerve. This "invasive" VNS was also used in a recent pilot trial of VNS in 20 human stroke survivors with arm weakness. 9 In that trial, participants were randomised in a cross-over trial to either 6 weeks of intensive repetitive task practice (RTP) paired with VNS or RTP alone. In the per-protocol analysis, the VNS group improved their Upper Extremity Fugl-Meyer (UFM) score by 9.6 points compared to only 3.0 in the RTP-only group (between-group difference 6.5 points, 95% CI 0.4-12.6; P =0.04). 10 Whilst such results are encouraging, recruitment into such studies can be challenging for many stroke survivors are unfit for, or are reluctant to undergo surgery.
Recently, devices that can stimulate the vagus nerve non-invasively have become available. We aimed to determine the feasibility, tolerability, acceptability and safety of taVNS alongside RTP in stroke survivors with arm weakness following a stroke. We also determined the responsiveness-to-change of a range of rehabilitation outcome measures. Our findings will be used to inform the design of a future randomized trial of taVNS in stroke recovery.
Materials and Methods
This was a single-group pre-post intervention study. (2) were participating in any other research trial (3) had aphasia or cognitive difficulties severe enough to interfere with the informed consent process, task specific practice or communication of adverse events, (4) were pregnant or trying to get pregnant, (5) had a pacemaker or other implanted electrical device or (6) had severe spasticity (a Modified Ashworth Score 12 ≥3).
Sample size
We aimed to recruit a minimum of 12 participants as this is the minimum number required for a pilot/feasibility study 13 .
Outcome Measures
At the initial study visit, demographics, time since stroke, medication and vascular risk factors were obtained from participants. Hospital records and imaging results were viewed to record the size, location and precise date of the stroke. Two measures of upper limb movement and functional independence were assessed by the study physiotherapists: Upper Limb Fugl-Meyer (UFM) 14 and Action Recovery Arm Test (ARAT) 15, 16 . The participants also completed the following self-report measures: Modified Rankin Score (mRS), 17 Barthel Index, 18 Stroke Impact Scale (SIS), 19 Motor Activity Log (to measure use of the impaired limb in a variety of activities of daily living such as putting on shoes, drying hands, wiping a kitchen counter, using a television remote-control), 20 Patient-health Questionnaire (PHQ9) 21 ,
Generalised Anxiety Disorder 7 (GAD7) 22 and the Fatigue Assessment Scale 23 . The upper limb assessment scales was chosen because they capture the three domains of the International Classification of Functioning framework (impairment, function and participation) and incorporate objective as well as patient-reported outcome measures. Mood and anxiety were assessed as depression is a common complication of stroke and can impede rehabilitation as well as being potentially moderated by VNS. 24 All outcomes were measured again at the final treatment visit.
An electrocardiogram (ECG) was performed at baseline and at the end of each treatment session and the pulse (beats/min) rate, PR interval (ms), QRS duration (ms) and the corrected QT interval (ms) were recorded by the ECG machine. These were reviewed by JR and compared to baseline values. At each treatment visit, details of any side effects or difficulties experienced by participants during or after the intervention were recorded.
Intervention
The taVNS ear piece was fitted to the participants left ear such that the electrodes made contact with the concha (Figure 1 ). The intensity (mA) of stimulation was increased slowly by increments of 0.1 mA until the participant's reported maximum tolerable level and this intensity used for the rest of the session. The manufacturers (Cerbomed, Germany)
reprogrammed the stimulator to avoid the usual "ramp-up" (increase in mA) each time it was switched on. The pulse width was 0.1 ms and frequency 25 Hz.
Exercise programmes were tailored to the participant's impairments and goals. Each session began with large-range arm movements, frequently involving bilateral activities, either reciprocal or symmetrical and using equipment e.g. pedals, a pole or ball to assist independent movement. This was followed by repetitive task-specific movements e.g. turning cards, manipulating or lifting objects, opening and closing bottles (Table 1 ).
Approximately 7 -10 tasks with 30 to 50 repetitions were attempted (aiming for > 300 repetitions in total) per session. 25 The physiotherapist turned the stimulation "on" by pressing a button on the stimulator unit when the participant began to move the arm and "off" when the movement ceased. The frequency of sessions (3 times a week for 6 weeks) matched that used in the trial of invasive VNS 12 which reported improvements in function post stroke.
The number of arm movements per session were recorded.
Qualitative interviews
After the final treatment session, a semi-structured interview was conducted. The topic guide incorporated open-ended questions regarding the acceptability of the electrical stimulation.
The interviews allowed participants to share experiences that the researchers had not anticipated. 26 Interviews lasted 30-45 minutes and were recorded and transcribed verbatim.
Data analysis
Analyses were mainly descriptive, as the study was not powered for inferential analysis. We for a scale, we calculated the number of participants who achieved this change (e.g. for the
Upper-limb fugl-meyer, MCID = 10 points) 28 , and for ARAT (5.7 points)) 29 .
We calculated effect sizes (Cohen's d) for each measure using the following formula: (mean post-intervention minus mean at-baseline) divided by the standard deviation at baseline.
We regarded a meaningful change in the ECG parameters to be a) a change of 20% in resting heart rate and/or b) a 10% change from baseline PR/QRS or QTc or c) a deviation outside the normal reference range for any of these values or d) the development of a non-sinus rhythm Qualitative data were analysed with a thematic framework approach 30 . Transcripts were first coded according to themes decided a priori that were focused on the specific aims of the study, such as experience of the stimulation, experience of the physiotherapy and wider experiences of the study. Data relating to each theme was placed into a matrix enabling data for each participant and each theme to be carefully compared. Transcripts were then checked to ensure there were no elements were overlooked by the pre-existing themes. The themes arising and the analytical process were examined by a second reviewer to ensure rigour.
Criteria for Proceeding to a definitive trial Pre-specified success criteria included the following: 1) More than 2/3 planned treatment sessions attended 2) All participants achieving mean task repetitions per session >300 3) <1/3 participants experiencing side effects from intervention 4) absence of serious adverse events.
Results
Twenty interested participants were contacted. After telephone screening, 18 were invited for further assessment. Of these, 13 met inclusion criteria (Figure 2 ). Reasons for exclusion included spasticity (n=2), aphasia (n=1) and absence of active arm movement (n=2).
The 13 participants [(10 males, mean (SD) age 64.5 (6.9), median (IQR) years since stroke Table 1 shows the type and number of arm repetitions performed by one participant as they progressed through the programme.
Only three participants reported side effects. These included light-headedness in one participant and general tiredness and fatigue in two. Only the former was considered by the researchers to be possibly attributed to the taVNS. No associated ECG changes were seen. or not at all (Table 2 ). There were no significant changes in ECG recordings for rate, PR/QRS or QTc interval.
Qualitative Interviews
Two key themes were the experience of the intervention, (the perceived advantages of the intervention.
The experience of the intervention.
Most participants felt that the electrical stimulation was comfortable. Only one participant felt that the sensation stung when it was turned up too high.
Most participants were happy with the frequency and duration of visits. Some participants commented that the exercises were tiring.
The participant complaining of light-headedness was uncertain if this was related to the taVNS. He and two others reported tiredness and some muscle stiffness but all three believed this was related to the intensity of the exercise programme rather than the taVNS.
Perceptions of effectiveness
Eleven out of the twelve participants felt that they had improved upper limb function, mentioning e.g. improved dexterity, strength and/or flexibility with tasks such as putting a coat on, brushing hair and gripping objects in the kitchen.
"You know it all used to be really terribly heavy; it was an effort to lift it because it was heavy and now I can, I can do it"
Discussion
We recruited 13 participants who between them attended 215 treatment sessions in which transcutaneous auricular VNS (taVNS) was delivered concurrently with repetitive task practice (RTP). Only one participant withdrew from the study. Despite the added treatment with taVNS, all 12 remaining participants were able to perform >300 arm movements per hour -the threshold which triggers plasticity in animal models. 25 The treatment was generally well tolerated and almost all felt that their arm function improved during the study.
Of the 9 outcome measures we assessed, the UFM was the most sensitive to change (Table   2 ), increasing by a mean (SD) of 17 (7.8) points. The UFM scale measures the "impairment"
domain of the International Classification of Functioning and is designed specifically for use in post-stroke hemiplegia, measuring actual recovery rather than compensatory movement.
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UFM was also the outcome which improved significantly in the trial of invasive VNS in stroke motor recovery 9 and has been recently deemed a core outcome in stroke recovery.
32
Transcutaneous VNS has the advantage over invasive VNS in that it does not require surgery.
Furthermore, whilst invasive VNS can cause cough, hoarseness, voice alteration and parenthesis 33 , to our knowledge there have been no reports of serious adverse reactions to taVNS in the literature to date. Our high retention rate and the positive feedback from participants further suggest that a future trial of taVNS in stroke recovery is feasible.
There were, however some potential limitations to this study. First, it would have been preferable to conduct the qualitative interviews with a researcher not directly involved in the therapy. However, the participants were open in describing suboptimal aspects of the programme and felt immediately at ease being interviewed by a familiar researcher. Second, at this stage we can only speculate about the size of any beneficial effect of the taVNS combined with RTP alone. However, a recent Cochrane review (11 trials, 749 participants) found that RTP alone produced surprisingly modest improvements in arm function post stroke regardless of time interval since stroke. 34 In that review, the standardized mean difference (i.e. the mean effect size taking into consideration differences in motor outcome scales between studies) for RTP versus usual care/placebo was 0.25 (95% confidence interval (CI) 0.01 to 0.49). 34 In contrast, we observed an effect size for UFM of 0.68 with 10/12
participants achieving an increase of at least 10 points in UFM score. Our findings are thus in keeping with a potentially powerful effect of taVNS but this needs to be further tested in a controlled trial setting. Such a trial could deploy "sham" taVNS by inverting the electrodes in the ear 35 which does not activate central vagal connections. 
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